25 October 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Presentation of Midkine Antibody Program Update at the Festival of Biologics Conference
Abstract accepted at leading biological therapeutics conference
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, is pleased to announce that its Midkine antibody program update will be presented on 3 November 2022 at the Festival of Biologics conference in Basel, Switzerland. The ROQA1 (CAB 102) and ROQA2 (CAB101) programs have demonstrated efficacy in validated in vivo models of breast cancer and osteosarcoma resulting in a significantly reduced metastatic index (P<0.05), safety in rodent and non-human primates toxicology studies, and scalable production of CAB102.
The poster is embargoed until the presentation at the conference but will then be available at the Roquefort Therapeutics website.
The title of the presentation poster and presenter details will be published on the conference website today:
https://www.terrapinn.com/conference/festival-of-biologics/Posters.stm
-Ends-
Enquiries:
| Roquefort Therapeutics plc | |
| Stephen West (Chairman) / Ajan Reginald (CEO) | +44 (0)20 3918 8633
|
| Hybridan LLP (Joint Broker) Claire Louise Noyce
Optiva Securities Limited (Joint Broker) |
+44 (0)203 764 2341 |
| Christian Dennis
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
| +44 (0)20 3411 1881
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· MK cell therapy with direct and NK-mediated anti-cancer action; and
· siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
